AGLE News and Press, Aeglea BioTherapeutics Inc. From 05/06/21

Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency Includes Sponsored Diagnostic Testing and Services for Patients with Suspected Arginase 1 Deficiency PR Newswire A...

Aeglea BioTherapeutics (AGLE) announces that it has completed patient randomization for PEACE (Pegzilarginase Effect on Arginase 1 Deficiency Clinical Endpoints), the pivotal Phase 3 clinical trial investigating pegzilarginase for the treatment of Arginase 1 Deficiency ((ARG1-D)).ARG1-D is a ...

Aeglea BioTherapeutics Completes Patient Randomization for PEACE, its Pivotal Phase 3 Clinical Trial of Pegzilarginase for the Treatment of Arginase 1 Deficiency Topline Results Expected in the Fourth Quarter of 2021; Target Enrollment Exceeded Pegzilarginase has the Potenti...

Aeglea BioTherapeutics to Participate in Two Virtual Investor Conferences in April 2021 PR Newswire AUSTIN, Texas, April 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of hum...

Aeglea BioTherapeutics (AGLE) has signed an agreement with Immedica Pharma AB giving the latter commercialization rights to pegzilarginase for the treatment of Arginase 1 Deficiency in Europe and the Middle East.Under the terms of the agreement, Immedica will make an upfront payment of $21.5 ...

Aeglea BioTherapeutics and Immedica Announce Commercialization Agreement for Pegzilarginase for the Treatment of Arginase 1 Deficiency in Europe and Middle East Aeglea receives $21.5 million upfront with up to approximately $130 million in milestone payments and royalties in the...

Aeglea BioTherapeutics (AGLE): FY GAAP EPS of -$1.52 beats by $0.04.Cash, cash equivalents, marketable securities and restricted cash of $148.1MPress Release For further details see: Aeglea BioTherapeutics EPS beats by $0.04

Aeglea BioTherapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Corporate Highlights Phase 3 PEACE Study Enrollment Expected to Complete in March; Topline Data Expected in Fourth Quarter Received U.S. Rare Pediatric Disease Designation for AGLE-177 for...

Aeglea Biotherapeutics (AGLE) gains 5.5% premarket on disclosing 9.9% stake (4.9M shares) by Baker Bros.Source For further details see: Aeglea Biotherapeutics climbs 5.5% on ownership disclosure

Gainers: [[SNSE]] +17.5%. [[ABCL]] +8.3%. [[AGLE]] +7.6%. [[OLED]] +5.9%. [[EOLS]] +5.4%.Losers: [[CRWD]] -7.0%. [[ARDX]] -6.9%. [[NK]] -6.6%. [[CATB]] -3.2%. [[ISEE]] -3.1%. For further details see: SNSE, AGLE, CRWD and ISEE among after-hours movers